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Background: Several World Health Organization (WHO) initiatives aim to improve the accessibility of safe and
effective medicines for children. A first step in achieving this goal is to obtain a baseline measure of access to
essential medicines. The objective of this project was to measure the availability, prices, and affordability of
children’s medicines in Guatemala.
Methods: An adaption of the standardized methodology developed by the World Health Organization and Health
Action International (HAI) was used to conduct a cross sectional survey to collect data on availability and final
patient prices of medicines in public and private sector medicine outlets during April and May of 2010.
Results: A subset of the public sector, Programa de Accesibilidad a los Medicamentos (PROAM), had the lowest
average availability (25%) compared to the private sector (35%). In the private sector, highest and lowest priced
medicines were 22.7 and 10.7 times more expensive than their international reference price comparison.
Treatments were generally unaffordable, costing as much as 15 days wages for a course of ceftriaxone.
Conclusions: Analysis of the procurement, supply and distribution of specific medicines is needed to determine
reasons for lack of availability. Improvements to accessibility could be made by developing an essential medicines
list for children and including these medicines in national purchasing lists.
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Children in poorer countries are more likely to die from
treatable conditions than those in higher resource settings
because they do not receive appropriate or timely medica-
tions [1]. This is also true in Guatemala, where poverty
contributes to the country’s high mortality rate for chil-
dren under the age of five [2]. Millennium Development
Goal 4 (MDG4) states that a two-thirds reduction in mor-
tality from 1990 to 2015 in children younger than five
years is essential for global development [3]. Compared to
the rate of mortality in 1990, Guatemala will need to in-
crease the rate of decline in childhood deaths from 75.8 to
25.3 deaths per 1000 to achieve the MDG goal by 2015
[4]. To assist member countries with achieving MDG4,* Correspondence: anganson21@gmail.com
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reproduction in any medium, provided the orthe WHO constructed the first Essential Medicines List
for Children (EMLc) and launched the “Make Medicines
Child Size” effort in December of 2007. This initiative
aims to improve the accessibility of safe, effective and
quality medicines for children by promoting awareness
and action through research, regulatory measures and
changes in government policy.
A vital first step to improving medicine access for chil-
dren is measuring the availability and prices of essential
medicines present on pharmacy shelves and in national
medicines lists. Data on medicine stock deficits and un-
affordable prices creates an evidence base to inform the
development of national and regional policies. A recent
survey of essential medicines for children in Africa
exposed the severe lack of medicines for children in cen-
tral medicine stores, hospitals, pharmacies and national
medicine lists in 14 different countries [5]. The objective
of this study is to measure access to children’s medicinesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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used in Africa [6,7].Sources of medicines in Guatemala
The Ministry of Health network is a publically funded
group of primary, secondary and tertiary healthcare cen-
ters that render services to approximately 70% of the
population in Guatemala [8]. Tertiary care hospitals pro-
vide a variety of medical specialty and outpatient ser-
vices and offer medicines on an inpatient basis only, free
of charge. The proportion of families who utilize these
services or seek treatment elsewhere to care for their
sick children is unknown.
The Ministry of Health also operates PROAM, which
are pharmacies that offer medicines from Lista Basica, a
formulary of medicines for common diseases afflicting
the population. PROAM was created in 1998 by the
Guatemalan Ministry of Health to ensure equal access to
quality medications at reasonable prices [9]. The Ministry
of Health establishes “contrato abierto”, a system for set-
ting suppliers and prices in which the government negoti-
ates contracts with pharmaceutical companies to purchase
medications [10,11]. The government then distributes
medicines from Lista Basica needed to stock PROAM
pharmacies which are subsequently sold to consumers.
PROAM consists of approximately 514 outpatient medi-
cine outlets throughout the country [12]. The law requires
that all medications sold must comply with the United
States pharmacopeia XXIV quality standards.
The most numerous medicine outlets in Guatemala
are privately owned pharmacies, which number close to
4043 establishments throughout the country [12]. This
makes the private sector an important source of medi-
cines in Guatemala. There are various laws governing
the structure and sanitation of all pharmacies, but no
laws regulate the acquisition or prices of medications in
the private sector [13-15]. Other sources of medication
in Guatemala include Social Security hospitals, private
hospitals, dispensing doctors, non-governmental organi-
zations (NGOs) and unregistered dispensaries.Methods
We conducted a survey of the availability, prices and af-
fordability of children’s medicines in Guatemala using an
adaption of the standardized methodology developed by
the World Health Organization (WHO) and Health Ac-
tion International (HAI) [7]. A validation study of the
WHO/HAI survey methodology conducted in Peru in
2005 found that focusing on commonly used medicines
yields sufficient and valid results [16]. We collected data
on the availability and final patient prices of medicines
in a subsector of public and private sector medicine out-
lets during April and May of 2010.Selection of medicine outlets
We selected six regions as survey areas for data collec-
tion: Guatemala City, Escuintla, Jalapa, Quetzaltenango,
Retalhuleu, and Alta Verapaz. The major urban center of
Guatemala City was selected and an additional five
“departamentos” or states were chosen at random from
those which could be reached within a day’s travel from
Guatemala City. These departamentos are all comprised
of a collection of urban and rural areas, however, the ac-
tual survey areas within each departamento varied
demographically.
In each survey area, four to seven private and PROAM
sector medicine outlets were randomly selected from a
list of pharmacies registered by the Ministry of Health.
The actual number surveyed was limited by accuracy of
the Ministry of Health registry list and available man-
power to carry out the surveys. The private sector sam-
ple included 29 outlets and the PROAM sector included
21 outlets. A tertiary public hospital located in each sur-
vey area was also included when permission was
granted, yielding a sample of four hospitals. Pharmaceut-
ical stores held by private dispensing doctors and non-
governmental organizations were not surveyed due to
lack of time and resources.
Selection of medicines
The “Better Medicines for Children Project” specifies a core
list of the EMLc to be surveyed, representing medicines
commonly used in the treatment of a range of conditions
associated with childhood illness prevalent in low income
countries [6]. The list specifies the child-specific dosage
form and strength for 23 medicines, as well as one device.
We included 22 medicines and one device from the core
list in the Guatemala survey. Artemether + lumefantrine
was excluded, as it is used for P. falciparum species of
malaria, which is not common in the Americas. Prima-
quine was selected as an alternate malarial medication, as
it is effective against P. vivax, the prevalent species of mal-
aria in Guatemala. When alternate formulations were
registered in Guatemala, these were added into the list of
index medicines and surveyed. In total, 27 medicines and
one device were surveyed in Guatemala (Table 1).
For each medicine surveyed, we recorded the highest
and lowest price medicine available. In the PROAM sec-
tor, manufacturer was also recorded to determine if the
product was brand or generic. Medicines in the public
hospitals were free of charge to hospitalized patients so
only availability was measured.
Data collection and analysis
Data collection took place during April and May of 2010.
Six data collectors were trained according to the WHO/
HAI methodology and pilot data collection was conducted.
The data collectors visited medicine outlets and collected
Table 1 List of medicines surveyed in Guatemala
No. Disease Name Strength Dosage form
1 Asthma Salbutamol* 100 mcg/dose Inhaler
2 Asthma Beclomethasone 100 mcg/dose Inhaler
3 Dehydration Zinc 20 mg Dispersible tab
4 Dehydration Oral Rehydration Solution 500 ml Solution
5 Dehydration Oral Rehydration Solution, powder* To make 500ml Powder
6 Infectious disease Amoxicillin 100 mg/ml Pediatric drops
7 Infectious disease Amoxicillin 125 mg/5ml Suspension
8 Infectious disease Amoxicillin* 250 mg/5ml Suspension
9 Infectious disease Amoxicillin + Clavulanic Acid 125 mg+ 31.25mg/5ml Suspension
10 Infectious disease Amoxicillin + Clavulanic Acid* 250 mg+ 62.5mg/5ml Suspension
11 Infectious disease Benzathine Penicillin G* 1.2 M units/vial Injection
12 Infectious disease Ceftriaxone* 500 mg/vial Injection
13 Infectious disease Chloramphenicol 1 g/vial Injection
14 Infectious disease Cotrimoxazole (Trimethoprin + Sulfamethoxazole)* 8 + 40 mg/ml Suspension
15 Infectious disease Gentamicin* 10mg/ml Injection
16 Infectious disease Procaine Penicillin G* 4 M units/vial Injection
17 Malaria Primaquine 15mg Cap/tab
18 Pain/inflammation Ibuprofen 200 mg Cap/tab
19 Pain/inflammation Paracetamol* 25 mg/ml syrup/susp
20 Pain Morphine Sulfate 10mg/ml Injection
21 Xerophthalmia Vitamin A 50,000 units Cap/tab
22 Tuberculosis Isoniazid 100 mg Cap/tab
23 Anemia Ferrous Salt* 125 mg/5ml Suspension
24 Seizure Disorder Diazepam 5 mg/ml Injection
25 Seizure Disorder Carbamazepine 100 mg/5ml Suspension
26 Seizure Disorder Phenobarbital 3mg/ml Oral liquid
27 Seizure Disorder Phenytoin 25 or 30mg/5ml Suspension
28 Device – asthma Spacer n/a n/a
* =medicine listed on Lista Basica.
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standard data collection form specific to the medicines
being surveyed in Guatemala. The data collectors entered
survey data into the pre-programmed MS Excel Workbook
provided as part of the WHO/HAI methodology. Data col-
lection was verified in roughly 10% of pharmacies, data
were double-entered and the data checker function on the
spreadsheet was used to identify data entry errors.
Three medicines were excluded from the analysis leav-
ing a total of 24 medicines and 1 device for analysis.
Phenytoin and phenobarbital suspensions were excluded
as the incorrect strengths of the medications were
printed on the data collection sheets. Beclomethasone
inhaler was omitted from the analysis because although
it was included on the core list of children’s medicines
for the survey, it was deleted from the EMLc in 2009
[17]. Of note, it was not found in any of the pharmaciessurveyed in Guatemala. We calculated the availability of
individual medicines as the percentage of sampled medi-
cine outlets where the medicine was found. Data are
reported in aggregate and by private vs. public sector
pharmacies. We also report mean (average) availability
for the list of medicines surveyed.
Cross-country comparisons
To facilitate cross-country comparisons, medicine prices
obtained during the survey were expressed as ratios rela-
tive to a standard set of international reference prices:
Medicine  Price  Ratio  MPRð Þ ¼  median  local  unit  price
international  reference  unit  price
Medicine price ratios were calculated only for medi-
cines with price data from at least 4 medicine outlets.
The exchange rate used to calculate MPRs was 1 US
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taken from OANDA.com on the first day of data collec-
tion [18].
We used the 2009 Management Sciences for Health
(MSH) reference prices, taken from the International
Drug Price Indicator Guide [19]. These reference prices
are the medians of recent procurement prices offered
for generic products by for-profit and not-for-profit
suppliers to international not-for-profit agencies.Affordability
We assessed the affordability of treating eight of com-
mon conditions causing high rates of morbidity and
mortality of children in Guatemala by comparing the
total cost of medicines prescribed at a standard dose to
the daily wage of the lowest paid unskilled government
worker at 56 quetzales ($6.87 USD per day) at the time
of the survey. For acute conditions, treatment duration
was defined as a full course of therapy, while for chronic
diseases, the affordability of a 30-days' supply of medi-
cines was determined. Though it is difficult to assess
true affordability, treatments costing one days' wage or
less were considered affordable [7].
This study was approved by the University of California,
San Francisco Committee on Human Research, approval
number H2758-35862.Results
Availability of medicines on the day of data collection
As shown in Table 2, the availability of individual medi-
cines varied by type of medicine and sector. Average
availability of all surveyed medications was very low.
Public tertiary hospitals had the highest availability of
medicines found with an average of 46% (range 28-56%)
of medicines found in each outlet. Average availability in
the private sector was 35% (range 10-52%) for lowest
priced medicines. Average availability for a second,
higher priced medicine when a lower price medicine was
found, was 12% in the private sector.
The PROAM sector had the lowest availability at 25%
(range 5-43%). In the PROAM sector, generics were the
predominant product type available, with 98% (142/145)
of medicines found as generics. Although we expected
that only medicines found on the Lista Basica would be
stocked, some of these medicines had low availability in-
cluding ferrous salt suspension (24%), gentamicin injec-
tion (33%) and procaine penicillin G (29%). When we
limited the analysis to the 11 survey medicines found
only on the Lista Basica (Table 1), availability increased
to 57% (range 9-82%) in the PROAM sector. The avail-
abilities of individual medicines in the PROAM, public
tertiary hospitals and private sectors are shown in
Table 3.PROAM and private sector patient prices
As shown in Table 4, lowest price medicines are generally
sold at 1.73 times their international reference price in the
PROAM sector. Half of the lowest priced generic medi-
cines were priced at 1.24 (25th percentile) to 2.32 (75th
percentile) times their international reference price, show-
ing moderate variation in medicine price ratios across in-
dividual generic medicines in the PROAM sector.
In contrast, substantial variation exists in median price
ratios in the private sector. We compared prices between
lowest and highest priced products for six medicines for
which more than one price option was found. In the pri-
vate sector, higher price medications cost twice as much,
on average, as their lowest priced equivalents. Higher
priced medicines were 22.67 times more expensive than
their international reference price. The cost of half of
these medicines ranged from 11.21 (25th percentile) to
35.51 (75th percentile) times their international reference
price. Lowest price medicines were 10.46 times their
international reference price with half of these medicines
priced at 5.57 (25th percentile) to 16.99 (75th percentile)
times their international reference.
Comparison of patient prices in the PROAM and private
sectors
Median price ratios were substantially higher in the pri-
vate sector compared to the PROAM sector. Nine medi-
cines that were found in both PROAM and private sectors
had data available for price comparisons. As the median
MPR was 1.61 and 10.32 for PROAM and private sectors,
respectively, final patient prices were 6.41 times higher in
the private sector than in the PROAM sector.
Affordability of standard treatment regimens
As shown in Table 5, lowest price medicines in the pri-
vate sector were less affordable than in the PROAM sec-
tor for most conditions, with standard treatment costing
a days' wage or more. Medicines costing over a days’
wage include ceftriaxone injection for susceptible infec-
tion costing 15 days wages and carbamazepine suspen-
sion for seizure disorders costing 6.6 days wages.
Discussion
The availability of essential children’s medicines is low in
both the public and private sectors in Guatemala. Avail-
ability is lowest in the public sector, but there is incon-
sistent pricing and poor affordability of medicines in the
private sector. Furthermore, formulations of medications
that are preferable for use in children were often hard to
find. Of the 30 medicine formulations in the survey
protocol, seven were not assessed because they are not
registered in Guatemala [6]. These consisted of dispers-
ible (3) and chewable (2) tablets, oral liquid (1) and
intrarectal solution (1); all formulations preferred for use
Table 2 Availability of lowest price medications by sector
Public hospital Public PROAM Private
Medicines not found in any Amoxicillin pediatric drops Amoxicillin pediatric drops Chloramphenicol injection
outlets * Amoxicillin suspension Amoxicillin suspension Ferrous Salt suspension
125mg 125mg Gentamicin injection
Amoxicillin-Clav Amoxicillin-Clav Isoniazid tablets
suspension 125mg suspension 125mg Morphine Sulfate
Amoxicillin-Clav Carbamazepine injection
suspension 250mg suspension Primaquine tablets
Carbamazepine Chloramphenicol Zinc dispersible tablets
suspension Injection
Ibuprofen tablets Diazepam Injection







Medicines found in less than 25% of outlets Primaquine tablets Ferrous salt suspension Amoxicillin pediatric
Vitamin A tablets Oral Rehydration drops
Zinc dispersible tablets Solution Amoxicillin-Clav






Medicines found in 25 to 49.9% of outlets Ceftriaxone Injection Amoxicillin suspension
Gentamicin injection 125mg





Medicines found in 50 to 74.9% of outlets Amoxicillin suspension Amoxicillin suspension Benzathine Penicillin G
250mg 250mg injection
Chloramphenicol Amoxicillin-Clav Ibuprofen tablets
Injection 250mg suspension Oral Rehydration
Isoniazid tablets Cotrimoxazole Solution, powder
Oral Rehydration Solution (Trimethoprim+ Sulfamethoxazole Salbutamol (Albuterol) Inhaler
Paracetamol (Acetaminophen)
Medicines found in 75% or more of outlets Benzathine Penicillin G Benzathine Penicillin G Ceftriaxone injection
injection injection Cotrimoxazole
Ceftriaxone Injection Oral Rehydration (Trimethoprim +
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Table 3 Availability of individual medicines in the public, PROAM and private sector
Percentage of outlets where medicine was found
Public sector
(n = 4 outlets)
PROAM sector
(n = 21 outlets)
Private sector
(n = 29 outlets)




Amoxicillin Pediatric Drops 0.0% 0.0% 6.9% 20.7%
Amoxicillin Suspension 125mg 0.0% 0.0% 6.9% 34.5%
Amoxicillin Suspension 250mg 50% 61.9% 6.9% 48.3%
Amoxicillin-Clav Suspension 125mg 0.0% 0.0% 10.3% 41.4%
Amoxicillin-Clav Suspension 250mg 0.0% 57.1% 3.4% 13.8%
Benzathine Penicillin G Injection 75% 90.5% 20.7% 69.0%
Carbamazepine Suspension 0.0% 0.0% 3.4% 20.7%
Ceftriaxone Injection 100% 47.6% 27.6% 82.8%
Chloramphenicol Injection 50% 0.0% 0.0% 0.0%
Cotrimoxazole
(Trimethoprim+ Sulfamethoxazole)
100% 57.1% 51.7% 89.7%
Diazepam Injection 75% 0.0% 0.0% 13.8%
Ferrous salt suspension 75% 23.8% 0.0% 0.0%
Gentamicin Injection 100% 33.3% 0.0% 0.0%
Ibuprofen 0.0% 0.0% 13.8% 58.6%
Isoniazid 50% 0.0% 0.0% 0.0%
Morphine Sulfate Injection 75% 0.0% 0.0% 0.0%
Oral Rehydration Solution 50% 9.5% 69.0% 96.6%
Oral Rehydration Solution, powder 100% 81.0% 0.0% 72.4%
Paracetamol (Acetaminophen) 75% 71.4% 41.4% 82.8%
Primaquine 25% 0.0% 0.0% 0.0%
Procaine Penicillin G 100% 28.6% 3.4% 27.6%
Salbutamol (Albuterol) Inhaler 0.0% 42.9% 34.5% 62.1%
Spacer 0.0% 0.0% 3.4% 13.8%
Vitamin A 25% 9.5% 0.0% 13.8%
Zinc 25% 0.0% 0.0% 0.0%
Table 2 Availability of lowest price medications by sector (Continued)
Cotrimoxazole Solution, powder Sulfamethoxazole)
(Trimethoprim + Oral Rehydration
Sulfamethoxazole) Solution
Diazepam Injection Paracetamol








*in the PROAM sector, the Lista Basica determines the medications stocked in the pharmacy. Medications not found in any PROAM outlets were medications not
on the Lista Basica.
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Table 4 Median price ratios of lowest priced medicines,
private and PROAM sector patient prices
Medicine name Lowest price medication
MPR (25th-75th percentile)
Private sector PROAM sector
Amoxicillin Suspension 125mg 18.86 (14.65-19.54) n/a
Amoxicillin Suspension 250mg 13.88 (9.60-19.55) 1.85 (1.56-2.04)
Amoxicillin-Clav Suspension 125mg 6.13 (4.50-6.13) n/a
Amoxicillin-Clav Suspension 250mg 2.53 (2.16-2.76) 0.60 (0.53-0.70)
Benzathine Penicillin G Injection 35.54 (19.33-41.78) 4.51 (3.16-5.86)
Carbamazepine Suspension 3.04 (2.70-3.37) n/a
Ceftriaxone Injection 13.20 (7.65-18.70) 1.61 (1.10-1.65)
Cotrimoxazole suspension 10.32 (6.42-16.48) 1.37 (1.20-1.82)
Diazepam Injection 19.70 (16.08-26.26) n/a
Gentamicin Injection n/a 2.77 (2.08-3.46)
Ibuprofen 31.54 (30.07-36.08) n/a
Oral Rehydration Solution, powder 5.01 (4.38-7.51) 1.88 (1.25-2.75)
Paracetamol (Acetaminophen) 6.26 (4.72-7.65) 1.05 (0.89-1.70)
Procaine Penicillin G 10.46 (9.15-12.30) 2.46 (2.04-2.65)
Salbutamol (Albuterol) Inhaler 4.94 (3.49-5.56) 1.20 (0.94-1.21)
Vitamin A 15.13 (12.45-15.58) n/a
* Medicine price ratios (MPRs) were calculated only for medicines with price
data from at least 4 medicine outlets.
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cines for children is related to low prescriber demand
similar to the case with magnesium sulfate in Zambia,
or exclusion from the contrato abierto, the central gov-
ernment purchasing mechanism, due to high purchasing
prices [20]. Guatemala is subject to rules and regulations
under Trade Related Aspects of Intellectual Property
Rights (TRIPS). Essential medicines that have been
reformulated to be better suited for children may be
under patent and therefore more expensive in Guate-
mala for up to 5 to 15 years after becoming generic in
the United States [11]. Another factor that may be re-
sponsible for a dearth of registered child friendly formu-
lations may be difficultly obtaining the product if it is
not manufactured in the country or nearby. As sug-
gested in previous literature, studies of local prescribing
practices and government purchasing are required to
fully answer these questions [5]. Development of a na-
tional essential medicines list that includes children’s
medicines could increase demand from providers and
guide purchasing decisions [21].
Among the surveyed medicines, originator brands were
almost never available in the PROAM sector as the gov-
ernment contracts with generic pharmaceutical companies
to procure less expensive medications. In addition, the
availability of generic medicines in the PROAM sector
was exceptionally low with only about one quarter ofindex medicines stocked in each outlet. These findings are
similar to a recent study on the accessibility of children’s
medicines in 14 African countries, where essential chil-
dren’s medicines were available at central medicine stores
15 to 75% of time with only 3 medicine outlets containing
over 50% of medicines [5]. Our findings are also consistent
with a number of pricing and availability surveys that have
been conducted for adult medicines for both acute and
chronic diseases [22-25]. These studies show that avail-
ability of essential medicines is lower in the public than
the private sector, varies by country, and that medicines
for chronic conditions are less available than those for
acute conditions.
Seven medications were not found at all in the private
sector. One medication, chloramphenicol injection, was
not stocked due to concerns about its toxicity. One would
expect the remainder of these medicines to be found at
the hospital level and therefore, not stocked in outpatient
outlets. However, as the availability in hospitals is low,
friends or family of hospitalized patients often go to alter-
nate locations such as private retail pharmacies to pur-
chase medications. Even the poorest patients in
Guatemala seek medicines from the private sector [26].
Diarrheal disease is one of the major causes of mortality
in children under five in Guatemala [8]. Although oral re-
hydration powders for reconstitution and premixed solu-
tions for treatment of diarrhea were available in the
PROAM and private sectors, oral zinc was unavailable in
these sectors and the mean availability was only 25% in
the hospital setting. Zinc is included on the EMLc due to
its benefit in treating children with diarrhea [27].
Antibiotics for treating pneumonia and other respira-
tory infections in children should be available for use as
empiric treatment, to decrease a major cause of morbid-
ity in children [8]. While ceftriaxone was found quite
frequently in the private and public sectors, it was only
available in about half of the PROAM outlets. Amoxicil-
lin and amoxicillin-clavulanic acid were available most
frequently in 250mg/5ml concentration. When child ap-
propriate concentrations are not available, pharmacy
employees must calculate the dose. This could lead to
adverse drug events as pharmacy employees in low in-
come countries may need additional training [28].
In the PROAM sector, affordability of lowest price
medicines was reasonable compared to the private sector
where many of lowest priced treatments cost more than
the daily wage of a lowest paid government employee. In
the private sector, the most unaffordable treatments
were for seizure disorder with carbamazepine (6.6 days
wages) and infections with ceftriaxone (15 days wages).
Carbamazepine is an ongoing treatment for a chronic
condition, making it even less affordable. Given that 24%
of the population in Guatemala is living below the inter-
national poverty line of less than $2/day, treatments
Table 5 Affordability: Number of days' wages of worker making lowest paid government wages needed to purchase
standard treatments
Disease condition and ‘standard’ treatment Day’s wages to pay for treatment
Condition Drug name, strength,
dosage form










Child up to 10 years: 125mg






Child over 10 years: 250mg






Child 1–6 years: 125mg (=5ml) x






Child over 10 years: 250mg
(=5ml) x 3 x 7 days = 105 ml
2.6 0.6
Seizure Disorder Carbamazepine Suspension
100mg/5ml
Maintenance treatment: 5mg/kg x
18 kg* x 3 x 30 days = 8100mg or




Ceftriaxone 500 mg vial Child under 50 kg: Maximum 1




Cotrimoxazole 18 kg x 4mg/kg = 72 mg TMP x 2
x 7 days = 1008 mg. 126 ml total
for 7 days.
0.8 0.1
Dehydration Oral Rehydration Solution,
powder to make 500 mL
Moderate Dehydration: 75mL/kg
x 18 kg = 1350
0.1 n/a





5 year old child: 15mg/kg x 18 kg
x 4 x 3 = 3240 mg (=130 mL)
0.5 0.1
Asthma Salbutamol 100 mcg/dose
inhaler
1 inhaler of 200 doses 1.3 0.3
Xerophthalmia Vitamin A 50,000 units Child 1–12 years: 200,000 units x
3 doses
0.4 n/a
*Weight of average 5 year old child in Guatemala = 18 kg [31,32].
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addition, treatment costs refer to medicines only and do
not include the additional costs of consultation and
diagnostic tests. Finally, families who need medications
for more than one child may be confronted with insur-
mountable drug costs. These findings are consistent with
other studies of affordability of adult medicines showing
that chronic medicines, in particular, are unaffordable
for many populations [22,23,25,30].
A major strength of this study is the use of a previously
validated methodology which allows for the measurement
of medicine prices and availability in a reliable and stan-
dardized way [16]. Additional strengths include training
and utilization of multiple check points to ensure quality
data collection, data entry and interpretation.
Limitations of the WHO/HAI methodology are con-
sistent with past surveys. Therapeutic alternatives or al-
ternate dosage forms were not assessed. The availability
data refers to the day of data collection at each particu-
lar facility in subsectors of the country and may not re-
flect average monthly or yearly availability of medicinesat individual facilities or throughout the entire country.
Also, the standard for determining the median price
ratio is the median of supplier prices. However, if sup-
plier prices are not available, buyer prices are substituted
to determine the median international reference price
for the different medications. This can lead to artificially
high or low reference price that isn’t necessarily indica-
tive of true median price paid internationally [25].
NGOs, private dispensing doctors and unregistered dis-
pensaries were not surveyed and their importance as a
source of medicines for those with low socioeconomic
status is unknown. Further investigation is warranted
into the amount that these sources contribute to accessi-
bility to medications in Guatemala.
Conclusion
The findings of this study can be used to structure policies
to improve the accessibility of children’s medicines in
Guatemala and help the country meet MDG4 in 2015.
Monitoring the availability and pricing of children’s essen-
tial medicines in Guatemala and other countries is crucial
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lists of all registered pharmacies are needed to facilitate
these analyses. Inclusion of the WHO’s Essential Medi-
cines List for children into national formularies and pur-
chasing lists such as the PROAM and contrato abierto
could improve the availability of essential children’s medi-
cines. Data should be collected on prescribing practices of
local pediatricians to detect deficiencies, if any, in rational
prescribing and develop educational programs to improve
prescribing of medicines from the EMLc [5]. The coordin-
ation of the WHO EMLc with national clinical practice
guidelines could promote physician use of essential medi-
cines. Further analysis of the procurement, supply and dis-
tribution of specific medicines is needed to determine
reasons for lack of availability [20].
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